Cover Image
市場調查報告書

Paras Biopharmaceuticals Finland Oy的產品平台分析

Paras Biopharmaceuticals Finland Oy - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 318938
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
Paras Biopharmaceuticals Finland Oy的產品平台分析 Paras Biopharmaceuticals Finland Oy - Product Pipeline Review - 2015
出版日期: 2015年03月26日 內容資訊: 英文 25 Pages
簡介

Paras Biopharmaceuticals Finland Oy正在開發及改善大腸菌及畢赤酵母方面的重組蛋白之生物學性製程及發現手法。提供最佳化Scale-up技術,臨床及商業性生產用產品。此外也開發骨質疏鬆症,類風濕性關節炎,代謝疾病,腫瘤等疾病所用之生技仿製藥技術。

本報告提供Paras Biopharmaceuticals Finland Oy的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Paras Biopharmaceuticals Finland Oy的基本資料

  • Paras Biopharmaceuticals Finland Oy概要
  • 主要資訊
  • 企業資料

Paras Biopharmaceuticals Finland Oy:R&D概要

  • 主要的治療範圍

Paras Biopharmaceuticals Finland Oy:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Paras Biopharmaceuticals Finland Oy:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Paras Biopharmaceuticals Finland Oy:藥物簡介

  • anakinra biosimilar
  • PB-3010
  • PB-3020
  • PB-3030
  • PB-4020
  • PPB-4010
  • teriparatide biosimilar

Paras Biopharmaceuticals Finland Oy:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Paras Biopharmaceuticals Finland Oy:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06892CDB

Summary

Global Markets Direct's, 'Paras Biopharmaceuticals Finland Oy - Product Pipeline Review - 2015', provides an overview of the Paras Biopharmaceuticals Finland Oy's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Paras Biopharmaceuticals Finland Oy's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Paras Biopharmaceuticals Finland Oy including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Paras Biopharmaceuticals Finland Oy's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Paras Biopharmaceuticals Finland Oy's pipeline products

Reasons to buy

  • Evaluate Paras Biopharmaceuticals Finland Oy's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Paras Biopharmaceuticals Finland Oy in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Paras Biopharmaceuticals Finland Oy's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Paras Biopharmaceuticals Finland Oy and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Paras Biopharmaceuticals Finland Oy
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Paras Biopharmaceuticals Finland Oy and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Paras Biopharmaceuticals Finland Oy Snapshot
    • Paras Biopharmaceuticals Finland Oy Overview
    • Key Information
    • Key Facts
  • Paras Biopharmaceuticals Finland Oy - Research and Development Overview
    • Key Therapeutic Areas
  • Paras Biopharmaceuticals Finland Oy - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Paras Biopharmaceuticals Finland Oy - Pipeline Products Glance
    • Paras Biopharmaceuticals Finland Oy - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Paras Biopharmaceuticals Finland Oy - Drug Profiles
    • anakinra biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PB-3010
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PB-3020
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PB-3030
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PB-3040
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PB-4020
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PPB-4010
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • teriparatide biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Paras Biopharmaceuticals Finland Oy - Pipeline Analysis
    • Paras Biopharmaceuticals Finland Oy - Pipeline Products by Target
    • Paras Biopharmaceuticals Finland Oy - Pipeline Products by Route of Administration
    • Paras Biopharmaceuticals Finland Oy - Pipeline Products by Molecule Type
    • Paras Biopharmaceuticals Finland Oy - Pipeline Products by Mechanism of Action
  • Paras Biopharmaceuticals Finland Oy - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Paras Biopharmaceuticals Finland Oy, Key Information
  • Paras Biopharmaceuticals Finland Oy, Key Facts
  • Paras Biopharmaceuticals Finland Oy - Pipeline by Indication, 2015
  • Paras Biopharmaceuticals Finland Oy - Pipeline by Stage of Development, 2015
  • Paras Biopharmaceuticals Finland Oy - Monotherapy Products in Pipeline, 2015
  • Paras Biopharmaceuticals Finland Oy - Preclinical, 2015
  • Paras Biopharmaceuticals Finland Oy - Pipeline by Target, 2015
  • Paras Biopharmaceuticals Finland Oy - Pipeline by Route of Administration, 2015
  • Paras Biopharmaceuticals Finland Oy - Pipeline by Molecule Type, 2015
  • Paras Biopharmaceuticals Finland Oy - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Paras Biopharmaceuticals Finland Oy - Pipeline by Top 10 Indication, 2015
  • Paras Biopharmaceuticals Finland Oy - Pipeline by Top 10 Target, 2015
  • Paras Biopharmaceuticals Finland Oy - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top